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Summary
Objective: The goal of this study was to characterize the proteoglycan (PG) production and processing by bone marrow stromal cells (BMSCs)
within a tissue engineered construct.
Methods: Bovine BMSCs and articular chondrocytes (ACs) were isolated from an immature calf, seeded into agarose gels, and cultured up to
32 days in the presence of TGF-b1. The localization of various PGs was examined by immunoﬂuorescence and histological staining. The role
of proteolytic enzymes in construct development was further investigated by examining the effects of aggrecanase and MMP inhibitors on PG
accumulation, aggrecan processing, and construct mechanics.
Results: BMSCs developed a matrix rich in sulfated-glycosaminoglycans (sGAG) and full-length aggrecan, but had low levels of versican. The
BMSC constructs had less collagen II and aggrecan compared to the AC constructs cultured under identical conditions. AC constructs also
had high levels of pericellular collagen VI, while BMSCs had a pericellular matrix containing little collagen VI and greater levels of decorin,
biglycan, and ﬁbronectin. Treatment with the aggrecanase inhibitor did not affect sGAG accumulation or the dynamic moduli of the BMSC
constructs. The MMP inhibitor slightly but signiﬁcantly inhibited sGAG accumulation and lowered the dynamic moduli of BMSC constructs.
Conclusions: The results of this preliminary study indicate that long-term culture of BMSCs with TGF-b1 promotes the development of an
aggrecan-rich matrix characteristic of native articular cartilage; however, BMSCs accumulate signiﬁcantly lower levels of sGAG and assemble
distinct pericellular microenvironments compared to ACs. PG turnover does not appear to play a major role in the development of tissue
engineered cartilage constructs by BMSCs.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Tissue engineering and regenerative therapies have the
potential to repair damage to articular cartilage and restore
long-term joint function. However, there are signiﬁcant
challenges for recreating a tissue with the appropriate
matrix composition and mechanical function1. The limited
availability of autologous chondrocytes, combined with their
rapid dedifferentiation during monolayer expansion2,
presents additional obstacles for cartilage engineering.
Stem cells and other progenitors are possible alternatives
to ACs, but it has yet to be established whether these cells
can develop into mature chondrocytes and produce a carti-
laginous matrix with the necessary mechanical properties.
Bone marrow stromal cells (BMSCs) are a heterogeneous
mixture of ﬁbroblastic cells, which contain populations of*Address correspondence and reprint requests to: Marc E.
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1092mesenchymal stem and progenitor cells3. BMSCs can
easily be isolated from the bone marrow by their ability to
adhere to tissue culture plastic and subsequently expanded
in vitro3,4, making them particularly attractive for tissue
engineering applications. In addition, progenitors within
BMSC cultures have the potential to differentiate along
chondrogenic, osteogenic, and adipogenic lineages3,5.
When cultured in three-dimensional environments, the
addition of various members of the transforming growth fac-
tor superfamily, including transforming growth factor beta-1
(TGF-b1), promotes expression of chondrocyte-speciﬁc
genes and proteoglycan (PG) synthesis6e8. Although
BMSC-seeded constructs accumulate a cartilage-like ma-
trix consisting of type II collagen and sulfated-glycosamino-
glycans (sGAG)9, the total amount of matrix and material
properties after 10 weeks are inferior to constructs devel-
oped with ACs10. Furthermore, it is unclear if the PG com-
position and organization produced by differentiating
BMSCs are characteristic of native articular cartilage.
PGs play an essential role in the load-bearing function of
articular cartilage. The main structural PG within cartilage is
aggrecan, which consists of a protein core with numerous
sGAG side chains11. The aggrecan molecules are linked
1093Osteoarthritis and Cartilage Vol. 16, No. 9to a hyaluronic acid backbone, forming a large macromole-
cule. Interactions between the negatively charged sGAG
chains and ions in the interstitial ﬂuid produce an osmotic
swelling pressure that is resisted by the collagen II network
and allows articular cartilage to bear high compressive
forces12, 13. While aggrecan is the most abundant PG within
the tissue, small amounts of other PGs, including perlecan,
decorin and biglycan, are found within the pericellular
matrix14, 15. These small PGs are known to interact with
growth factors and matrix proteins, such as collagen VI
and ﬁbronectin, and may play a more direct role in regulat-
ing cell function16. Additionally, the large PG versican is
highly expressed in pre-cartilage condensations17 and
developing limb cartilage but is replaced by aggrecan dur-
ing maturation18. The temporal changes in the PG expres-
sion proﬁle that occur during development motivate further
investigation into the composition of the matrix produced
by progenitor cells undergoing in vitro chondrogenesis.
Synthesis and turnover of the extracellular matrix (ECM)
are critical for the homeostasis of healthy articular cartilage.
Aggrecan catabolism is tightly regulated by the activity of
multiple proteases, including matrix-metalloproteinases
(MMPs)19 and aggrecanases11. These enzymes cleave
the aggrecan core protein at speciﬁc locations and release
various sized fragments from the PG macromolecule20.
Cleavage can result in ‘‘destructive’’ aggrecanolysis, which
results in the loss of sGAGs from the tissue, and it is there-
fore closely linked to the tissue’s compressive properties21.
Aggrecan processing can also be ‘‘non-destructive’’ in
nature if proteases (primarily MMPs) act on previously
degraded molecules and do not cause additional release
of sGAGs22. Recent studies have identiﬁed a site within
the CS-1 region of the core protein that can be cleaved
by enzymes with m-calpain like activity23. Cleavage at this
site results in a destructive loss of sGAG in vitro and in
vivo and can be detected by the retention of w230 kDa
fragments bearing a neoepitope with the DLS sequence23.
Upregulation of MMP and aggrecanase activity occurs
during osteoarthritis and in response to inﬂammatory
cytokines24. In addition, TGF-b1 has been shown to stimu-
late both cartilage matrix synthesis and degradation25, 26.
Differences in aggrecan processing have also been
observed between ACs and meniscal ﬁbrochondrocytes,
which have higher endogenous levels of aggrecanase
activity and produce a matrix with more degraded aggre-
can27. Therefore, the inﬂuences of growth factor regulation
and cell type differences on proteolytic enzyme activity may
be important considerations for the use of progenitor cells in
developing engineered cartilage tissues.
Although TGF-b1 has been shown to promote aggrecan
gene expression and sGAG accumulation by BMSCs, it
remains unclear whether the actual matrix composition is
similar to that produced by fully differentiated chondrocytes.
Therefore, the goal of this study was to characterize the PG
production and processing by BMSCs within tissue engi-
neered constructs. Bovine BMSCs and ACs were seeded
into agarose gels and cultured up to 32 days in the
presence of TGF-b1. The localization of various PGs was
examined by immunoﬂuorescence and histological staining,
and the presence of speciﬁc matrix proteins known to
interact with these PGs was also determined by immunoﬂu-
orescence and western blot analysis. The role of proteolytic
enzymes in construct development was further investigated
by examining the effects of aggrecanase and MMP inhibi-
tors (MMP inh) on PG accumulation, aggrecan processing,
and construct mechanics. The results of this study illustrate
key differences in matrix synthesis and turnover betweenBMSCs and ACs. These ﬁndings provide new insights
into the chondrogenesis of BMSCs and their potential use
for articular cartilage regeneration.Materials and methodsMATERIALSImmature bovine hind limbs were from Research 87 (Marlborough, MA).
Recombinant human TGF-b1 was from R&D Systems (Minneapolis, MN),
and basic-ﬁbroblast growth factor (bFGF) was from Peprotech (Rocky Hill,
NJ). Type VIII agarose, agarase, bovine serum albumin (BSA), protease-
free chondroitinase ABC, 1,9-dimethylmethylene blue (DMMB), and Hoechst
dye 33258 were from SigmaeAldrich (St. Louis, MO). The ITSþ premix and
ProteinaseK were from BD Biosciences (San Jose, CA). Fetal bovine serum
(FBS) was from Hyclone (Logan, UT), and cell culture reagents, including
Dulbecco’s Modiﬁed Eagles Medium (DMEM), antibiotic/antimycotic, trypsin,
non-essential amino acids (NEAA), and phosphate buffered saline (PBS),
were from Invitrogen (Carlsbad, CA). Polyacrylamide gels (4e12% gradient)
and prestained standards were also from Invitrogen. The enzyme-ampliﬁed
chemiﬂuorescence (ECF) substrate was from GE Healthcare (Piskataway,
NJ), and the Protease Inhibitor Cocktail I was from Calbiochem (San Diego,
CA). The WST-1 assay kit was from BioVision (Mountain View, CA). The ag-
grecanase inhibitor (RO3310769) and the MMP inhibitor (RO1136222) were
gifts from Roche Palo Alto (Palo Alto, CA).
The collagen type II (ab300) and collagen type VI (ab6583) antibodies
were from Abcam (Cambridge, UK). Anti-sera for the aggrecan-G1 domain
(anti-G1)28, aggrecan-G3 domain (JSCCDG/Lec-7)28,29, and DLS neoepitope
(JSCDLS)23 were provided by John Sandy, Ph.D. (Rush University, Chicago,
IL), and the anti-decorin (LF-94)30 and anti-biglycan (LF-96)31 antibodies
were from Larry Fisher, Ph.D. (NIDCR, Bethesda, MD). Alexaﬂuor 488 anti-
rabbit IgG and Alexaﬂuor 594 anti-mouse IgG were from Molecular Probes
(Carlsbad, CA). The anti-ﬁbronectin antibody (IST-3) was from Sigmae
Aldrich (St. Louis, MO), and the anti-versican antibody (12C5)32 was from
the University of IowaDevelopmental Studies Hybridoma Bank (IowaCity, IA).CELL ISOLATIONBonemarrow was harvested from the tibiae and femora of an immature calf
and physically disrupted by passage through 50 ml and 10 ml serological pi-
pettes, followed by 16, 18, and 20 gage needles. The marrow was then
separated by centrifugation, and the fatty layer was removed. The remaining
heterogeneous mixture was rinsed with PBS and pre-plated for 30 min to re-
move the rapidly adherent cells. The remaining cells were then re-plated at
approximately 250,000 cells/cm2 on tissue culture plastic and cultured in
low-glucose DMEM, 1% antibiotic/antimycotic, 10% FBS, and 1 ng/ml basic-
FGF. After 3 days, the non-adherent cells were removed during the ﬁrst media
change. The remaining adherent BMSCs were expanded until nearly conﬂu-
ent, at which time they were trypsinized and replated at 6000 cells/cm2. Cells
were expanded twice more to near-conﬂuence before seeding in agarose.
ACs were isolated from the cartilage of the femoralepatellar groove and
femoral condyles of an immature calf. The cartilage tissue was minced
and digested overnight in 0.2% collagenase with agitation. Cells were ﬁltered
through a 70 mm mesh, followed by sequential centrifugation and rinsing to
remove the collagenase. The number of viable cells was counted by trypan
blue exclusion.CONSTRUCT SEEDING AND CULTUREBMSCs and ACs were seeded into 1.5% agarose gels at a density of
10 106 cells/ml. A 3% agarose solution in PBS was melted and cooled to
42 C. The agarose was mixed 1:1 with a suspension of 20 106 cells/ml
in PBS. The agarose-cell suspension was mixed thoroughly and pipetted be-
tween glass plates with 3 mm spacing. The gels were cooled at 4 C for
20 min and cylindrical punches were made with a 6 mm biopsy punch. The
gel constructs were moved to 24-well plates, and fresh media were added.
BMSC- and AC-seeded gels were cultured up to 32 days in serum-free me-
dium (DMEM, ITSþ, antibiotic/antimycotic, NEAA, HEPES, ascorbate) plus
10 ng/ml TGF-b1. This culture period was based on previous studies10 and
allowed for enough matrix accumulation to produce signiﬁcant increases in
construct strength and stiffness. All media were further supplemented with
1 mM aggrecanase inhibitor, 1 mM MMP inhibitor or the carrier only, 0.01%
DMSO (same concentration as inhibitors), and there were six samples per
condition. As previously reported, the aggrecanse inhibitor speciﬁcally tar-
gets ADAMTS-4/5 (A Disintegrin And Metalloproteinase with Thrombospon-
din Motifs e 4/5), while the MMP inhibitor acts on a broad range of
collagenases, gelatinases, and membrane type MMPs21. The doses used
in this study were based on previous work with bovine articular cartilage21
and a preliminary dose response study with BMSCs. Media were collected
and changed every 2 days.
1094 J. T. Connelly et al.: Proteoglycans in engineered cartilageIMMUNOFLUORESCENCE STAINING AND HISTOLOGYGel constructs were ﬁxed in 10% neutral buffered formalin for 4 h, rinsed
in PBS, and dehydrated in 70% ethanol. Samples were subsequently em-
bedded in parafﬁn and sectioned at 5 mm onto glass slides. Sections were
deparafﬁnized and rehydrated in water. sGAG were stained with Safranin-
O, and cell nuclei were counter-stained with hemotoxylin. For immunoﬂures-
cence staining, sections were deglycosylated with 0.1 U/ml chondroitinase
ABC for 1 h at room temperature and blocked with 5% BSA for 30 min. Sec-
tions were then stained with 10 mg/ml primary antibodies against aggrecan-
G1, aggrecan-G3, collagen II, versican, ﬁbronectin, or non-immune rabbit
IgG and a secondary solution with AlexaFluor 488 anti-rabbit IgG and
Hoechst dye. Co-staining was performed via sequential staining using pri-
mary antibodies against decorin or biglycan, and a secondary antibody,
AlexaFluor 488 anti-rabbit IgG, followed by a biotinylated primary antibody
to collagen VI and detection with avidin-AlexaFluor. Immunoﬂuorescent
slides were preserved with aqueous gel mount and imaged using a Zeiss
Axiovert 200 ﬂuorescence microscope (Heidelberg, Germany).WESTERN BLOT ANALYSISProteins and PGs for western blot analysis were extracted from the aga-
rose gel constructs in 4 M guanidine-HCl plus the protease inhibitor cocktail I
overnight at 4 C. Equal portions of the extracts or day 32 media samples
were pooled (N¼ 6/group) and precipitated in 100% ethanol plus 5 mM so-
dium acetate overnight at 20 C. The precipitated material was deglycosy-
lated with chondroitinase ABC, keratinase I, and keratinase II for 4 h at 37 C
in the presence of protease inhibitors. The extract material was then dried
and resuspended in a reducing loading buffer. Equal portions of the extract
or media samples (approximately 5 mg) were separated by electrophoresis
on 4e12% Triseglycine gradient gels and transferred to nitrocellulose mem-
branes. The membranes were blocked overnight with 1% non-fat dry milk at
4 C. The membranes were probed for 1 h at room temperature with primary
antibodies against collagen VI, decorin, biglycan, ﬁbronectin, aggrecan-G1,
aggrecan-G3, and the DLS neoepitope. Secondary detection was performed
with an anti-rabbit, alkaline phosphatase antibody. The membranes were de-
veloped with a ﬂuorescent ECF substrate and imaged using a Fuji FLA-3000
imaging system.sGAG AND VIABILITY QUANTIFICATIONFollowing protein extraction, the gel constructs were lyophilized and se-
quentially digested with ProteinaseK (1 mg/80 mg tissue) at 60 C overnight
and agarase (4 U/construct) at 45 C for 4 h. Construct digests, protein
extracts, and media samples were analyzed for sGAG content using the
DMMB assay33. The total sGAG content in the gel constructs was reported
as the sum of the extract and digest portions. In addition, day 32 media sam-
ples were analyzed for mitochondrial activity, indicative of cell viability, using
the WST-1 assay according to the manufacturer’s instructions. WST-1 activ-
ity and sGAG content were analyzed by one-way ANOVA and Tukey’s test
for post hoc analysis, and sGAG release was analyzed by a two-way AN-
OVA with time and media conditions as factors. Signiﬁcance was determined
by P< 0.05.MECHANICAL TESTINGConstructs were stored at 4 C in PBS supplemented with the protease
inhibitor cocktail for up to 24 h before mechanical testing. Immediately prior
to testing, each construct was weighed wet, and the diameter and thickness
were measured at three distinct locations on the construct. Each construct
was then placed in a custom, unconﬁned compression chamber ﬁxtured to
an ELF 3100 uniaxial testing frame (Bose, Minnetonka, MN) and a 250 g but-
ton-type load cell (Honeywell Sensotec, Columbus, OH). The construct was
immersed in PBS with protease inhibitors, positioned between smooth, im-
permeable platens, and preloaded to 10e20 mN. Using Wintest software
and the Dynamic Mechanical Analysis (DMA) package, the construct was
compressed to 10% strain at 100 mm/min and allowed to equilibrate to the
new strain state for 30 min. Following relaxation, the constructs were sinusoi-
dally compressed at 0.1 and 1 Hz with an amplitude of 1.5% strain. Dynamic
moduli were calculated and exported from the DMA software. The mechan-
ical testing data were analyzed by one-way ANOVA and Tukey’s test for post
hoc analysis. Signiﬁcance was determined by P< 0.05.ResultsECM ACCUMULATION AND LOCALIZATIONThe accumulation and localization of cartilage matrix
molecules by chondrocytes and BMSCs were examinedby immunoﬂuorescence and Safranin-O staining. After 32
days in TGF-b1 supplemented medium, Safranin-O staining
of the tissue constructs demonstrated that ACs and BMSCs
produced a PG-rich matrix (Fig. 1A). There was more
intense staining in the AC-seeded gels, particularly in the
interterritorial regions, than in the BMSC-seeded gels. In
addition, there were clear differences in the distribution of
sGAG throughout the constructs. AC samples had high
levels of sGAG throughout the construct, while BMSC
samples had primarily pericellular sGAG and less amounts
at the periphery of the construct (Fig. 1A, top). There also
appeared to be more heterogeneity within the BMSC
constructs, where many cells could be observed lacking
a dense pericellular matrix.
The speciﬁc species of PGs within the agarose gel
constructs were further examined by immunoﬂuorescence
staining of the aggrecan (G1 and G3) and versican core
proteins. AC and BMSC constructs stained intensely for
the aggrecan-G1 globular domain, with more aggrecan in
the AC samples (Fig. 1B). The distribution of G1 was similar
to the pattern of sGAG seen with the Safranin-O staining,
suggesting that the major PG within the constructs is aggre-
can. Positive staining for the G3 domain in both groups
indicated the presence of full-length aggrecan (Fig. 1C).
There also appeared to be higher levels of pericellular G3
in the BMSC constructs. Low levels of versican could be
detected with anti-sera raised against the hyaluronan
binding region for the BMSC constructs only (Fig. 1D).
The patterns of type II collagen accumulation were similar
to those of aggrecan. Collagen II deposition was highest in
the pericellular region, and the AC constructs had overall
greater amounts of collagen II than the BMSC constructs
(Fig. 1E). Combined with the PG staining, these results
demonstrate that both ACs and BMSCs produce a carti-
lage-like ECM composed of aggrecan and collagen II
when cultured with TGF-b1. However, the AC constructs
accumulated more matrix than the BMSC constructs and
with a more uniform distribution.PERICELLULAR MATRIX COMPOSITIONThe localization and abundance of pericellular matrix
proteins within the chondrocyte and BMSC constructs was in-
vestigated by immunoﬂuorescence staining and western blot
analysis. Intense pericellular staining for collagen VI was ob-
served around ACs throughout the construct, while the
BMSC constructs displayed little collagen VI staining
(Fig. 2A, B). In contrast, high levels of the small PGs,
decorin and biglycan, were present in the BMSC samples,
but not in the AC samples (Fig. 2A, B). BMSC constructs
also displayed greater amounts of pericellular ﬁbronectin, as
well as diffuse accumulation in the interterritorial region
(Fig. 2C). The ﬁbronectin distribution varied considerably in
the BMSC constructs, with the highest levels observed at the
periphery of the gel. The differential production of collagen
VI, decorin, biglycan, and ﬁbronectin between the ACs and
BMSCs was veriﬁed by western blot analysis of protein ex-
tracts from the tissue engineered constructs (Fig. 2DeG).
These results demonstrate distinct differences in the composi-
tion of the pericellular matrix produced by ACs and BMSCs.EFFECTS OF AGGRECANASE AND MMP INHIBITORS ON
MATRIX ACCUMULATIONTo investigate the role of proteolytic enzymes in ECM de-
position, additional BMSC-seeded constructs were cultured
Fig. 1. Safranin-O and immunoﬂuorescence images of day 32 constructs. (A) Safranin-O; (B) aggrecan-G1 globular domain, green; (C)
aggrecan-G3 globular domain, green; (D) versican hyaluronan binding domain, green; (E) type II collagen, green; (F) non-immune control.
DNA is blue in all images. Scale bar¼ 100 mm.
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of the day 32 constructs with the WST-1 mitochondrial activ-
ity assay indicated that there were no toxic effects of the
inhibitors on the BMSCs during long-term culture (Fig. 3A).
The inhibitors had no effect on the cumulative amount of
sGAG released to the media (Fig. 3B). However, addition
of the MMP inhibitor signiﬁcantly decreased sGAG accumu-
lation (Fig. 3C). These differences were relatively small com-
pared to the amount of sGAG produced by ACs. Consistent
with the Safranin-O staining, AC constructs contained ap-
proximately twice as much sGAG as the BMSC constructs.
Immunoﬂuorescence staining for collagen II indicated similar
levels of pericellular collagen II in all BMSC groups (Fig. 3D).AGGRECAN PROCESSING BY BMSCsThe effects of the aggrecanase and MMP inhibitors on
aggrecan processing were examined by western blot anal-
ysis of the construct extracts and conditioned media. Detec-
tion of the aggrecan core protein with the anti-G1 antibody
indicated that the aggrecan retained within the construct
was primarily full-length (450 kDa). Lower levels of pro-
cessed aggrecan could be detected at approximately
50 kDa, 120 kDa, and just below 250 kDa (Fig. 4A). The
proteolytic inhibitors did not appear to have an effect on
the detection of the full-length or processed forms of aggre-
can-G1. Similar analysis of the day 32 media samples
indicated that the aggrecan released to the media was
also full-length (Fig. 4A). The DLS neoepitope, generated
by m-calpain cleavage23,29, could be observed in the ex-
tracts of BMSC constructs. Interestingly, the aggrecanaseinhibitor appeared to reduce the amount of this form of ag-
grecan, but the MMP inhibitor appeared to have no effect on
DLS generation (Fig. 4B). Analysis of the aggrecan-G1
distribution in native articular cartilage revealed characteris-
tic patterns of ADAMTS-4/5 (68 kDa) and MMP (55 kDa)
mediated cleavage. Together, these results indicate that
the aggrecan within the BMSC constructs is primarily full-
length and that low levels of proteases, including m-calpain,
are active under the conditions examined.CONSTRUCT MECHANICSThe functional implications of matrix accumulation and
processing were evaluated by measuring the dynamic com-
pressive moduli at 0.1 Hz and 1.0 Hz (Fig. 5). By day 32,
BMSC constructs had signiﬁcantly higher (6.7) compres-
sive moduli than day 0 samples. The aggrecanase inhibitor
slightly, but signiﬁcantly, increased (1.1) the modulus at
1.0 Hz, and the MMP inhibitor slightly decreased (0.8)
the moduli at both frequencies. Consistent with the greater
amount of matrix accumulation, the AC constructs had dy-
namic compressive moduli of approximately 1 MPa, signiﬁ-
cantly higher (3.3) than the moduli of all the BMSC
constructs.Discussion
The objective of the present study was to examine the
composition, organization, and processing of PGs by
BMSCs within a tissue engineered construct. Bovine
Fig. 2. Immunoﬂuorescence and western blot analysis of the pericellular matrix. (A) Co-staining for collagen VI, red, and decorin, green; (B)
co-staining for collagen VI, red, and biglycan, green; (C) ﬁbronectin, green. DNA is blue in all images. Western blots of construct extracts for
(D) collagen VI, (E) decorin, (F) biglycan, and (G) ﬁbronectin. Scale bar¼ 100 mm.
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presence of TGF-b1, conditions known to promote chondro-
genic differentiation. Under these conditions, the major PG
produced by BMSCs was aggrecan, and the strong G3
staining and western blot analysis indicated that the
aggrecan was primarily full length. Previous studies have
reported increased versican deposition in BMSC pellet
cultures during the ﬁrst 2 weeks of exposure to TGF-b334;
however, the results of the current study demonstrate that
by day 32 there was little versican present in the BMSC-
seeded constructs. In addition, there were large amounts
of collagen II present within the constructs. Despite synthe-
sizing an ECM characteristic of articular cartilage, BMSCs
produced far less total matrix than chondrocytes under
the same culture conditions. Furthermore, there were
distinct differences in matrix organization and composition
of the pericellular environment between the two cell types.
These ﬁndings provide new insights into the chondrogenic
potential of BMSCs and the character of their ECM.
Consistent with previous ﬁndings10, AC constructs had
threefold higher dynamic compressive moduli than BMSC
constructs, and these differences in mechanical function
were most likely due to the higher levels of matrix accumu-
lation by ACs. Analysis of the sGAG released to the media
indicated that by day 32 both cell types were releasingsGAG at a constant rate, and ACs were releasing sGAG
at a higher rate than BMSCs. Previous reports have also
shown that after longer culture periods (up to 10 weeks),
bovine BMSCs still produced less sGAG than ACs10, sug-
gesting that there are fundamental differences in the pheno-
types of these cells, rather than a lag in matrix synthesis
during the initial stages of differentiation. Interestingly, there
appeared to be higher levels of sGAG in the interiors of the
BMSC gels, where hypoxic conditions may have enhanced
differentiation and sGAG synthesis35.
The regional variations in matrix accumulation within the
BMSC constructs revealed that for a given sample there
was signiﬁcant heterogeneity in the level of chondrogene-
sis. In addition, the presence of cells completely lacking
a PG-rich pericellular matrix indicated that not all of the cells
were undergoing chondrogenesis and that the initial popula-
tion of BMSCs was likely not a homogeneous population of
mesenchymal progenitors. Enriching the number of progen-
itors in the initial population of BMSCs by immuno-selection
or other methods may be a useful strategy for improving the
maturation of tissue engineered constructs36,37. A potential
limitation of this preliminary study was the use of cells from
only one animal. Although initial experiments have indicated
little donor variability in the chondrogenic potential of bovine
BMSCs (not shown), future studies will require a closer
Fig. 3. Inﬂuence of aggrecanase and MMP inhibitors on ECM production. (A) WST-1 analysis of mitochondrial activity following 32 days of
treatment with the aggrecanase (Agg Inh) or MMP(MMP Inh) inhibitors N¼ 4/group. (B) Cumulative sGAG released to the media, N¼ 6/group,
*P< 0.05 with BMSC only group. (C) Total sGAG accumulation within the construct at day 32, N¼ 6/group, *P< 0.05 with BMSC only group.
(D) Immunoﬂuroescence images of collagen II accumulation at day 32, green, and DNA, blue. Scale bar¼ 100 mm.
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animals. It is also important to note that plastic-adherent
BMSCs may not be an optimal cell source for cartilage
repair. Several recent reports indicate that progenitors
derived from bone marrow, the synovium, adipose, and
muscle display varying chondrogenic potentials in pellet
culture, with synovial cells synthesizing the greatest amount
of PGs38,39. Therefore, future efforts to optimize the isola-
tion of chondrogenic progenitors from other tissues may
also improve matrix accumulation and construct function.
The distinct differences in the pericellular matrices
between ACs and BMSCs provide additional insights into
the differentiation state of these cells and potential mecha-
nisms for regulating cell activity. The AC pericellular
environment had high levels of collagen VI, similar to native
cartilage40, while the BMSC pericellular matrix contained
little collagen VI and higher versican, ﬁbronectin, decorin
and biglycan. These results indicate that the BMSCs still re-
tained features of a stromal cell phenotype and were not yet
fully differentiated chondrocytes. The high ﬁbronectin
expression at the periphery of the construct had the inverse
distribution of sGAG and may represent a marker of less
differentiated cells41. A similar expression pattern has
been observed during limb development, where ﬁbronec-
tin is upregulated in pre-cartilage condensations of themesenchyme but decreases in mature cartilage42. Other
constituents of the pericellular matrix are also known to
regulate cell activity. In vivo, collagen VI interacts with de-
corin and biglycan43 and may aid in collagen II and ag-
grecan matrix assembly44. In addition, the small PGs
can bind TGF-b1 and inﬂuence its availability to cells45.
Given that chondrogenesis is a dynamic process, where
ECM production and turnover are constantly changing,
different cellematrix interactions may be required at spe-
ciﬁc stages of development, and the unique composition
of the BMSC pericellular matrix may be essential at this
point in the chondrogenic program. Clearly, the complex
interactions between cells, ECM, and growth factors
have the potential to regulate differentiation and tissue
development through multiple mechanisms, and additional
studies will be required to more completely understand
their role in chondrogenesis.
Matrix catabolism is a critical component of tissue devel-
opment and homeostasis, and perturbations in the balance
between synthesis and degradation can signiﬁcantly alter
cartilage composition and function21. In this study, aggreca-
nase and MMP inhibitors were employed to examine the
effects of proteolytic degradation in construct development.
In general, catabolic enzymes appeared to play a minor role
in matrix accumulation by BMSCs. Western blots for the
Fig. 4. Western blot analysis of aggrecan processing. (A) Detection of aggrecan-G1 domain in BMSC construct extracts and day 32 media
samples from control, aggrecanase (Agg Inh) or MMP (MMP Inh) inhibitors treatments. (B) Detection of the m-calpain generated neoepitope
(DLS) in construct extracts. (C) Detection of aggrecan-G1 in native articular cartilage.
Fig. 5. Construct mechanics. The dynamic compressive moduli of
day 0 and day 32 constructs measured at 0.1 Hz and 1.0 Hz.
*P< 0.05 with BMSC only group, N¼ 6/group.
1098 J. T. Connelly et al.: Proteoglycans in engineered cartilageaggrecan-G1 domain indicated that an abundant amount of
full-length aggrecan was present in the constructs, and
compared to native tissue, the patterns of aggrecan-G1
seen in the BMSC samples contained little ADAMTS-4/5
(68 kDa) or MMP (55 kDa) generated fragments11,46,
suggesting that the activity of these enzymes is low within
this system. The low molecular weight G1 species migrating
atw40 kDa in the media may be due to cross-reactivity with
link protein, as there is high sequence homology between
aggrecan-G1 and link protein. Low levels of aggrecan
processing may have resulted in the retention of high
molecular weight species within the pericellular matrix of
the BMSC gels, while greater protease activity in the AC
gels allowed the lower molecular weight aggrecan to enter
the intercellular matrix. Alternatively, the differences in PG
distribution between the AC and BMSC cultures may have
been due to differences in total matrix synthesis.
The minor bands at 120 kDa and 230 kDa in the G1 blots
were characteristic of m-calpain mediated cleavage at the
eGVA and eDLS sites, respectively23,29, and this ﬁnding
was further conﬁrmed using the anti-DLS antibody. Addition
of the aggrecanase inhibitor appeared to reduce m-calpain
like activity and provided a small but signiﬁcant improve-
ment in construct stiffness. Since the effects of the aggreca-
nase inhibitor on m-calpain function have not been directly
measured, the lower levels of DLS generation may have re-
sulted from either direct inhibition of m-calpain activity or
through feedback mechanisms involving reduced aggreca-
nase activity47. In contrast, the MMP inhibitor signiﬁcantly
decreased the total sGAG content and dynamic moduli of
the tissue constructs. Consistent with the theory that
MMP-mediated cleavage is non-destructive22, this effect
may have resulted from an impaired ability of MMPs to re-
move previously degraded aggrecan from the pericellular
matrix and subsequent down-regulation of new aggrecan
synthesis. In addition, blocking MMP activity may have in-
hibited autocrine growth factor signaling. In growth platecartilage, MMP-3 activates latent TGF-b48, and MMP-7 is
responsible for degrading the binding proteins of insulin-
like growth factor49. Based on the WST-1 activity and previ-
ous studies with these inhibitors, it does not appear that the
lower sGAG production was due to cytotoxic effects.
Overall, the ﬁndings of this study have important impli-
cations for future directions in cartilage tissue engineer-
ing. BMSC production of a PG-rich matrix consisting of
primarily intact aggrecan is a promising development for
the use of these cells in articular cartilage repair. Further-
more, the low proteolytic activity of differentiating BMSCs
may be advantageous if they are eventually implanted
into a cartilage defect. Despite these advances, BMSCs
1099Osteoarthritis and Cartilage Vol. 16, No. 9cultured in TGF-b1 supplemented medium do not differen-
tiate into mature chondrocytes after 32 days in agarose
gel culture. Additional biochemical stimuli, such as growth
factors50,51 or glucocorticoids52, have been shown to en-
hance chondrogenesis, and optimization of the speciﬁc
culture conditions may be necessary for chondrocyte mat-
uration. Mechanical stimuli53 and low-oxygen tension35
are also potential strategies for improving in vitro differen-
tiation and construct development. The distinct pericellular
matrices produced by ACs and BMSCs suggest that
cellematrix interactions play an important role in chondro-
genesis, and the design of scaffolds presenting speciﬁc
matrix proteins may be another approach for guiding dif-
ferentiation and ECM production. Finally, the results of
the present study demonstrate that a thorough under-
standing of progenitor cell phenotypes and differentiation
will be critical for future work and the development of
functional tissue replacements.Acknowledgements
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